Last Updated:
Create account to add to watchlist!

Health Assurance Acquisition Corp. - HAAC

  • Commons



    HAAC Vol: 62.1K

  • Warrants



    HAACW Vol: 23.7K

  • Units



    HAACU Vol: 51.5K

Average: 0
Rating Count: 0
You Rated: Not rated

Please log in to rate.

SPAC Stats

Market Cap: 516.1M
Average Volume: 129.2K
52W Range: $9.67 - $15.20
Weekly %: +0.20%
Monthly %: +0.10%
Inst Owners: 74


Target: Searching
Days Since IPO: 380
Unit composition:
Trust Size: 50000000.0M

🕵Stocktwit Mentions

T8skmod posted at 2021-11-26T12:12:00Z

$HAAC Twits Stats Today's Change 13% + 🚀

Tickstocks posted at 2021-11-24T09:44:07Z

$HAAC Twits Stats Today's Change 13% + 🚀

Arnold_Stockzennegger posted at 2021-11-23T15:36:10Z

$HAAC warrants back in buy range $CPUH $LUXA

tickeron posted at 2021-11-21T19:13:33Z

This is why Hedge Funds use A.I. $HAAC in +0.31% Uptrend, advancing for three consecutive days on October 25, 2021. View odds for this and other indicators:

SPACHawk posted at 2021-11-20T22:26:04Z

I haven't seen any SPAC so far who's burning as much money as $HAAC - If they don't get deal any time soon, I am not sure when they would get it?

macroaxis posted at 2021-11-18T14:04:34Z

$HAAC - Implied volatility is down to 0.0 for Health Assurance

DrFeelgood posted at 2021-11-16T19:13:27Z

$HAAC Live shot of me watching my warrants drop 7 cents in 2 minutes…

DrFeelgood posted at 2021-11-16T18:47:44Z

$HAAC Live shot of me watching my warrants spike 7 cents…

dollarbilldave posted at 2021-11-16T16:38:46Z

getting myself some $HAAC calls for .05🤣 love it.

Flipflop88 posted at 2021-11-16T14:17:56Z

$HAAC dead money or they still have something in the pipeline ?

dollarbilldave posted at 2021-11-16T01:23:14Z


sharlsz posted at 2021-11-15T15:20:51Z


Tickstocks posted at 2021-11-13T00:30:07Z

$HAAC Twits Stats Today's Change 13% + 🚀

Last10K posted at 2021-11-12T23:55:44Z

$HAAC just filed a 10-Q Quarterly Report with 38 sections and 2 exhibits. Access them all or just read their earnings:

cctranscripts posted at 2021-11-12T21:38:40Z

Health Assurance Acquisition Corp. Just Filed Its Quarterly Report: Net Income (Loss) Pe... $HAAC

risenhoover posted at 2021-11-12T21:30:31Z

$HAAC / Health Assurance Acquisition files form 10-Q

Quantisnow posted at 2021-11-12T21:19:31Z

$HAAC 📜 SEC Form 10-Q filed by Health Assurance Acquisition Corp. 45 seconds delayed.

Newsfilter posted at 2021-11-12T21:18:44Z

$HAAC Form 10-Q (quarterly report [sections 13 or 15(d)]) filed with the SEC

bobhenry posted at 2021-11-12T03:28:20Z

$HAAC Averaged down on warrants on today’s flash sale. Up to 90K of them. Probably should’ve gotten to 100K just for the sake of it haha

dollarbilldave posted at 2021-11-11T22:04:11Z

Can’t wait to wake up to a $HAAC deal we all gonna bank. Glen Tullman to the moon $HAAC to the moon

Adam081982 posted at 2021-11-11T14:35:49Z


mars_voltron posted at 2021-11-10T21:45:19Z

$HAAC how you guys feeling here?

dollarbilldave posted at 2021-11-09T23:13:27Z

can we get a $HAAC deal one time for the one time!!! what yall think about this one? patience will pay imo

sharlsz posted at 2021-11-09T19:46:40Z

$HAAC how is this possible that this sits since 1 Fucking year here 😂

DrFeelgood posted at 2021-11-09T17:34:44Z

$HAAC I see what’s going on. Color Series E funding. Not cool, Hemant.

DrFeelgood posted at 2021-11-09T17:16:51Z

$HAAC Bad sign warrants are dropping, hopefully nobody knows something.

KingMoney posted at 2021-11-08T20:42:32Z

$HAAC Nice sign warrants are climbing, hopefully someone knows something.

44milliondollarclub posted at 2021-11-07T15:02:55Z

$HAAC: My analysis based on price actions says, at the current price of $9.78, this stock is UNDERVALUED! Fair Price should be between $10.42-$12.50. My Sell Target from the fair price would be between $13.03-$14.59. 1 year ago from today, the stock was trading at $11.25 so at the current price, it's down -13.07%! 💲💸🚀📈🌑💰🗠🤑 Want me to analyze a stock in real-time, just tag me with any stock symbol & also follow me :) !

Arnold_Stockzennegger posted at 2021-11-06T00:56:31Z

$CPUH still amazed how $LUXA and $HAAC warrants get a premium and CPUH warrants can’t hold above $1. Oh well, bought a few more today.

newsoftwaredev posted at 2021-11-05T16:34:41Z

$HAAC glad I bought warrants while they were less than $1/each


Our officers, directors and director nominees are as follows: Name ​ ​ Age ​ ​ Position ​ Hemant Taneja ​ ​ ​ ​ 45 ​ ​ ​ Chairman and Chief Executive Officer ​ Quentin Clark ​ ​ ​ ​ 49 ​ ​ ​ Director ​ Stephen K. Klasko ​ ​ ​ ​ 66 ​ ​ ​ Director ​ Anita Pramoda ​ ​ ​ ​ 45 ​ ​ ​ Director ​ Jennifer Schneider, MD ​ ​ ​ ​ 45 ​ ​ ​ Director ​ Glen Tullman ​ ​ ​ ​ 61 ​ ​ ​ Director ​ Evan Sotiriou ​ ​ ​ ​ 46 ​ ​ ​ Chief Operating Officer ​ Hemant Taneja, our Chairman and Chief Executive Officer has been a managing partner at General Catalyst since 2002 and the founder of the firm’s Silicon Valley operations. Mr. Taneja partners with mission-driven founders building platform companies that are fundamentally aligned with the long-term interests of society. Mr. Taneja is an early investor in market-leading companies across many sectors of the economy like Anduril, Canva, Color, Gitlab, Grammarly, Gusto, Livongo, Ro, Samsara, Snap, and Stripe. Mr. Taneja’s primary investment thesis, known as “economies of unscale,” explores how 21st-century founders leverage AI-based mass personalization techniques to innovate and build platforms across all sectors of the economy. In Mr. Taneja’s 2018 book Unscaled, he builds on that thesis and articulates the need for accountability, transparency, and explainability in AI technologies as they permeate deeper into daily life. Mr. Taneja’s piece in Harvard Business Review, “The Era of Move Fast and Break Things is Over,” advocates for entrepreneurs and venture capitalists to adopt frameworks for responsible innovation and investing. Mr. Taneja is also the founder and Executive Chairman of Commure, a company that has partnered with major health systems to modernize the software infrastructure for the healthcare space since its inception in 2017. Mr. Taneja’s recently published book UnHealthcare, co-authored with Dr. Klasko, lays out their thesis for how the healthcare system needs to transform into a health assurance system to bring consumerism, affordability, and rational economic behavior to this important sector. In addition to his investment work, Mr. Taneja is the Co-Founder of Advanced Energy Economy, an organization focused on transforming energy policy in America since 2011; and is a Founding Board Member of the Khan Lab School, a nonprofit K-12 school dedicated to classroom innovation since 2014. Mr. Taneja sits on the Board of Fellows for the Stanford School of Medicine and teaches a course at the college on A.I., Entrepreneurship, and Society. More recently, Mr. Taneja was featured in Business insider’s “100 People Transforming Business” list. Quentin Clark, our Director, is a managing director at General Catalyst, a venture capital firm that partners with seed- to endurance-stage founders to help build companies that withstand the test of time. Since joining in 2020, Mr. Clark focuses on investing in healthcare and enterprise SaaS, software, and platforms concentrating on transforming the workplace. Since joining the firm, Mr. Clark has made investments in Kernel, Minio, Range, Sprout, and several yet to be announced companies. Mr. Clark is on the boards of Commure, Kernel, ThoughtSpot, Coda, and Minio. Prior to joining General Catalyst, Mr. Clark was CTO at Dropbox (NASDAQ: DBX) from 2017 to 2019, where he led the company’s engineering, product, design, growth, and IT teams. Mr. Clark worked with them through its IPO, its pivot to Dropbox Spaces, and drove the portfolio expansion, starting with the acquisition of HelloSign. Prior to Dropbox, Mr. Clark spent two decades with Microsoft between 1994 and 2014, starting as a software engineer, then product manager, and eventually leading the whole data platform business into Microsoft’s cloud, Azure. Mr. Clark then joined SAP from 2014 to 2016, first as CTO, then as Chief Business Officer, where he led strategy and product direction for the platform and ultimately for the company. 105 TABLE OF CONTENTS Mr. Clark is a graduate of the University of Massachusetts at Amherst (1994), where he earned a B.S. in Physics and double-majored in Computer Science and currently sits on the Advisory Board for the College of Information & Computer Sciences. Stephen K. Klasko, MD, MBA, our Director, has been a pioneer in using connected care to build health assurance for all—especially as we emerge from the COVID-19 crisis. As President and CEO of Philadelphia-based Thomas Jefferson University and Jefferson Health since 2013, Dr. Klasko has led one of the U.S.’s fastest growing academic health institutions based on his vision of the future of higher education. Jefferson Health focuses on managing the health of populations in southeastern Pennsylvania and southern New Jersey. Jefferson has the largest faculty based telehealth network in the country, the NCI-designated Sidney Kimmel Cancer Center, and an outpatient footprint that is among the most technologically advanced in the region. This year, Dr. Klasko published UnHealthcare, with Hemant Taneja, as well as the textbook, Patient No Longer: Why Healthcare Must Deliver the Care Experience that Consumers Want and Expect. Jefferson’s 14 hospitals handled the most patients with COVID-19 in Philadelphia during the Spring 2020 surge. The hospital’s strategy included immediate universal masking, early exchange of research with Italy, and a history of longtime pandemic planning. In 2020, Dr. Klasko was named the first Distinguished Fellow of the World Economic Forum. Dr. Klasko attended medical school in Philadelphia at Hahnemann University (1978), built his practice as an obstetrician in Allentown, and served as dean of Drexel University’s College of Medicine (2000-2004). Dr. Klasko moved to Tampa, Florida, where he was dean of the Morsani College of Medicine and CEO of USF Health at the University of South Florida (2004-2013). Anita V. Pramoda, our director, has been the CEO of Owned Outcomes, Inc., a health analytics software company, since 2014. Ms. Pramoda has also served as the Chairperson of the Board of Directors of the Federal Reserve Bank of San Francisco (Los Angeles) since 2016, and as a board member (and Chair of Compensation Committee) of Health Catalyst, Inc., (NASDAQ: HCAT), a provider of data and analytics technology and services to healthcare organizations, since 2016. Since 2020, Ms. Pramoda has also been a board member (and Chair of Audit Committee) of GoHealth (NASDAQ: GOCO), a digital marketplace for health insurance. Previously, Ms. Pramoda served as a member of the board of directors of Dignity Health Foundation, from 2013 to 2017, Allscripts Healthcare, LLC (NASDAQ: MDRX), from 2013 to 2016, and as Chief Financial Officer at Epic Systems Corporation, from 2009 to 2012. Ms. Pramoda holds a Master in Business Administration degree from the University of Pennsylvania—The Wharton School (2004). Jennifer Schneider, MD, our Director, has been the President of Livongo since 2018, where she is responsible for product, data science, engineering, marketing, clinical operations, and growth strategy. Dr. Schneider previously served as the company’s Chief Medical Officer from 2015 to 2018, where she led the company’s strategic clinical product vision, data science, clinical trials, and the organization’s certified diabetes educators and coaches. Dr. Schneider is the author of Decoding Health Signals: Silicon Valley’s Consumer-First Approach to a New Era of Health, which offers a guide to the depth of the chronic conditions problem facing the industry today and explores how companies are using big data analytics and artificial intelligence to reinvent care delivery for people with chronic conditions. Dr. Schneider was recently named to Modern Healthcare’s List of Top Clinical Executives. Prior to Livongo, Dr. Schneider held several key leadership roles at Castlight Health from 2010 to 2015, most recently as Chief Medical Officer. Dr. Schneider also has held leadership roles as a health outcomes researcher and Chief Resident at Stanford University from 2005 to 2006, and she has practiced medicine as an attending physician at Stanford University, the VA Palo Alto Health Care System, and Kaiser Permanente. Dr. Schneider has an undergraduate degree from the College of the Holy Cross (1997), a Doctor of Medicine degree from Johns Hopkins School of Medicine (2002), and a Master of Science degree in Health Services Research from Stanford University (2010). Dr. Schneider completed her internal medicine residency at Stanford University Hospital. 106 TABLE OF CONTENTS Glen Tullman, our Director, is the Executive Chairman and Founder of Livongo (NASDAQ: LVGO), the consumer first digital health pioneer committed to empowering people with chronic conditions to live better and healthier lives. Mr. Tullman is dedicated to finding a cure for diabetes and other chronic conditions—and to keeping people healthy until these cures are found. A visionary leader and entrepreneur, Mr. Tullman previously ran two public companies that changed how health care is delivered. Before Livongo, Mr. Tullman served as Chief Executive Officer of Allscripts, which during his tenure from 1998 to 2012 was a leading provider of electronic health records, practice management, and electronic prescribing systems. Mr. Tullman took Allscripts public in 1999. Prior to Allscripts, Mr. Tullman was Chief Executive Officer of Enterprise Systems from 1997 to 1998, which he also took public and then sold to McKesson/HBOC. Mr. Tullman is the author of On Our Terms: Empowering the New Health Consumer, in which he proposes new solutions to address the chronic-condition epidemic facing our country. A strong proponent of philanthropy, Mr. Tullman was honored in 2019 with a Robert F. Kennedy Human Rights Ripple of Hope Award for his career focused on improving the safety, empathy, and efficiency of our healthcare system. Mr. Tullman also serves as a Chancellor to the International Board of the Juvenile Diabetes Research Foundation and as a Board Member of the American Diabetes Association. Mr. Tullman has an undergraduate degree from Bucknell University (1981) and a Master of Arts from the University of Oxford (1982). Evan Sotiriou, our Chief Operating Officer, has served in several senior management capacities of General Catalyst since 2019. Prior to that, Mr. Sotiriou served as the CFO for OrbiMed, which invests globally across the healthcare industry, from 2011 to 2019. Mr. Sotiriou also acted as the Vice President of GSC Group from 2000 to 2008, Managing Director of Clearlake Capital Management, L.P. from 2008 to 2010 and subsequently as the Chief Financial Officer for Archer Capital Management, L.P. from 2010 to 2011.Mr. Sotiriou holds an AB from Dartmouth College. Number and Terms of Office of Officers and Directors Our board of directors is divided into three classes, with only one class of directors being elected in each year, and with each class (except for those directors appointed prior to our first annual meeting of stockholders) serving a three-year term. In accordance with the Nasdaq corporate governance requirements, we are not required to hold an annual meeting until one year after our first fiscal year end following our listing on Nasdaq. The term of office of the first class of directors, consisting of                 , will expire at our first annual meeting of stockholders. The term of office of the second class of directors, consisting of                 and     , will expire at our second annual meeting of stockholders. The term of office of the third class of directors, consisting of                 and                 , will expire at our third annual meeting of stockholders. Prior to the completion of an initial business combination, any vacancy on the board of directors may be filled by a nominee chosen by holders of a majority of our alignment shares. In addition, prior to the completion of an initial business combination, holders of a majority of our alignment shares may remove a member of the board of directors for any reason. Pursuant to an agreement to be entered into on or prior to the closing of this offering, our sponsor, upon and following consummation of an initial business combination, will be entitled to nominate three individuals for election to our board of directors, as long as the sponsor holds any securities covered by the registration and stockholder rights agreement. Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint persons to the offices set forth in our amended and restated certificate of incorporation as it deems appropriate. Our amended and restated certificate of incorporation will provide that our officers may consist of one or more chairman of the board, chief executive officer, president, chief financial officer, vice presidents, secretary, treasurer and such other offices as may be determined by the board of directors. Director Independence Nasdaq listing standards require that a majority of our board of directors be independent. Our board of directors has determined that Stephen K. Klasko, Anita Pramoda, Jennifer Schneider and Glen Tullman are 107 TABLE OF CONTENTS “independent directors” as defined in the Nasdaq listing standards. Our independent directors will have regularly scheduled meetings at which only independent directors are present. Executive Officer and Director Compensation None of our executive officers or directors have received any cash compensation for services rendered to us. Commencing on the date that our securities are first listed on Nasdaq through the earlier of consummation of our initial business combination and our liquidation, we will reimburse an affiliate of our sponsor for office space, secretarial and administrative services provided to us in the amount of $10,000 per month. In addition, our sponsor, executive officers and directors, or their respective affiliates will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments that were made by us to our sponsor, executive officers or directors, or their affiliates. Any such payments prior to an initial business combination will be made using funds held outside the trust account. Other than quarterly audit committee review of such reimbursements, we do not expect to have any additional controls in place governing our reimbursement payments to our directors and executive officers for their out-of-pocket expenses incurred in connection with our activities on our behalf in connection with identifying and consummating an initial business combination. Other than these payments and reimbursements, no compensation of any kind, including finder’s and consulting fees, will be paid by the company to our sponsor, executive officers and directors, or their respective affiliates, prior to completion of our initial business combination. After the completion of our initial business combination, directors or members of our management team who remain with us may be paid consulting or management fees from the combined company. All of these fees will be fully disclosed to stockholders, to the extent then known, in the proxy solicitation materials or tender offer materials furnished to our stockholders in connection with a proposed business combination. We have not established any limit on the amount of such fees that may be paid by the combined company to our directors or members of management. It is unlikely the amount of such compensation will be known at the time of the proposed business combination, because the directors of the post-combination business will be responsible for determining executive officer and director compensation. Any compensation to be paid to our executive officers will be determined, or recommended to the board of directors for determination, either by a compensation committee constituted solely by independent directors or by a majority of the independent directors on our board of directors. We do not intend to take any action to ensure that members of our management team maintain their positions with us after the consummation of our initial business combination, although it is possible that some or all of our executive officers and directors may negotiate employment or consulting arrangements to remain with us after our initial business combination. The existence or terms of any such employment or consulting arrangements to retain their positions with us may influence our management’s motivation in identifying or selecting a target business but we do not believe that the ability of our management to remain with us after the consummation of our initial business combination will be a determining factor in our decision to proceed with any potential business combination. We are not party to any agreements with our executive officers and directors that provide for benefits upon termination of employment. Committees of the Board of Directors Upon the effectiveness of the registration statement of which this prospectus forms a part, our board of directors will have three standing committees: an audit committee, a nominating committee and a compensation committee. Subject to phase-in rules and a limited exception, the rules of Nasdaq and Rule 10A-3 of the Exchange Act require that the audit committee of a listed company be comprised solely of independent directors. Subject to phase-in rules and a limited exception, the rules of Nasdaq require that the compensation committee and the nominating committee of a listed company be comprised solely of independent directors. Audit Committee Upon the effectiveness of the registration statement of which this prospectus forms a part, we will establish an audit committee of the board of directors. Anita Pramoda, Jennifer Schneider and Glen Tullman will serve as 108 TABLE OF CONTENTS members of our audit committee. Our board of directors has determined that each of Anita Pramoda, Jennifer Schneider and Glen Tullman are independent under the Nasdaq listing standards and applicable SEC rules. Anita Pramoda will serve as the Chairman of the audit committee. Each member of the audit committee is financially literate and our board of directors has determined that Anita Pramoda qualifies as an “audit committee financial expert” as defined in applicable SEC rules. The audit committee is responsible for: • meeting with our independent registered public accounting firm regarding, among other issues, audits, and adequacy of our accounting and control systems; ​ • monitoring the independence of the independent registered public accounting firm; ​ • verifying the rotation of the lead (or coordinating) audit partner having primary responsibility for the audit and the audit partner responsible for reviewing the audit as required by law; ​ • inquiring and discussing with management our compliance with applicable laws and regulations; ​ • pre-approving all audit services and permitted non-audit services to be performed by our independent registered public accounting firm, including the fees and terms of the services to be performed; ​ • appointing or replacing the independent registered public accounting firm; ​ • determining the compensation and oversight of the work of the independent registered public accounting firm (including resolution of disagreements between management and the independe

Holder Stats

1 0
% of Shares Held by All Insider 0.00%
% of Shares Held by Institutions 56.74%
% of Float Held by Institutions 56.74%
Number of Institutions Holding Shares 74

Mutual Fund Holders

Holder Shares Date Reported Value % Out
Blackrock Funds-Health Sciences Opportunity Portfolio 1747926 2021-05-30 17601614 3.3300000000000005
BlackRock Health Sciences Trust II 1361273 2021-06-29 13626342 2.59
Highland Fds I-NexPoint Merger Arbitrage Fund 109900 2021-06-29 1100099 0.21
Blackrock Health Sciences Trust 90235 2021-06-29 903252 0.16999999999999998
Pacific Select Fund-Health Sciences Portfolio 76534 2021-06-29 766105 0.15
Fidelity NASDAQ Composite Index Fund 57066 2021-07-30 556964 0.11
Thrivent Partner Healthcare Portfolio 47585 2021-06-29 476325 0.09
ETF Series Solutions-Defiance Next Gen SPAC Derived ETF 16913 2021-06-29 169299 0.03
iShares BlackRock Future Health ETF 2816 2021-08-30 27371 0.01

Institutional Holders

Reporting Date Hedge Fund Shares Held Market Value % of Portfolio Quarterly Change in Shares Ownership in Company
2021-11-16 Schonfeld Strategic Advisors LLC 34,264 $340,000 0.0% 0 0.062%
2021-11-16 Jane Street Group LLC 56,397 $550,000 0.0% -268.0% 0.102%
2021-11-16 UBS Group AG 6,525 $64,000 0.0% -23.5% 0.012%
2021-11-16 Millennium Management LLC 865,857 $8,470,000 0.0% -42.1% 1.564%
2021-11-16 CNH Partners LLC 79,520 $780,000 0.0% +165.1% 0.144%
2021-11-15 Fortress Investment Group LLC 500,000 $4,890,000 0.3% +972.1% 0.903%
2021-11-15 General Catalyst Group Management LLC 2,311,624 $22,610,000 1.2% +3.9% 4.174%
2021-11-15 Berkley W R Corp 88,679 $870,000 0.1% +553.0% 0.160%
2021-11-15 Marshall Wace LLP 832,260 $8,140,000 0.0% 0 1.503%
2021-11-15 Royal Bank of Canada 108,515 $1,060,000 0.0% -30.5% 0.196%
2021-11-15 Morgan Stanley 25,205 $250,000 0.0% -73.5% 0.046%
2021-11-15 Athanor Capital LP 217,854 $2,130,000 0.3% -4.1% 0.393%
2021-11-15 Glazer Capital LLC 363,368 $3,550,000 0.1% +361.2% 0.656%
2021-11-15 CSS LLC IL 130,634 $1,280,000 0.1% 0 0.236%
2021-11-15 Penserra Capital Management LLC 14,575 $140,000 0.0% -13.8% 0.026%
2021-11-15 HBK Investments L P 600,000 $5,870,000 0.0% +9.1% 1.084%
2021-11-15 Dark Forest Capital Management LP 144,676 $1,420,000 0.5% 0 0.261%
2021-11-12 PEAK6 Investments LLC 25,793 $250,000 0.0% 0 0.047%
2021-11-12 Weiss Asset Management LP 1,724,837 $16,870,000 0.4% +78.2% 3.115%
2021-11-12 Sculptor Capital LP 1,571,382 $15,370,000 0.1% +313.1% 2.838%
2021-11-12 Cohanzick Management LLC 8,210 $80,000 0.0% 0 0.015%
2021-11-12 Crestline Management LP 18,000 $180,000 0.0% 0 0.033%
2021-11-12 Credit Suisse AG 21,208 $210,000 0.0% 0 0.038%
2021-11-12 Magnetar Financial LLC 72,239 $710,000 0.0% +16.5% 0.130%
2021-11-10 Goldman Sachs Group Inc. 1,208,358 $11,820,000 0.0% -4.0% 2.182%
2021-11-09 ATW Spac Management LLC 88,000 $860,000 0.2% 0 0.159%
2021-11-05 Lincoln National Corp 23,555 $230,000 0.0% -7.8% 0.043%
2021-10-25 Exos Asset Management LLC 11,987 $120,000 0.1% 0 0.022%
2021-10-06 IFP Advisors Inc 12,840 $130,000 0.0% -28.8% 0.023%
2021-08-24 Flow Traders U.S. LLC 17,099 $170,000 0.0% 0 0.031%
2021-08-23 Morgan Stanley 95,046 $950,000 0.0% -65.7% 0.172%
2021-08-17 Brookfield Asset Management Inc. 175,000 $1,750,000 0.0% +8.6% 0.316%
2021-08-17 Millennium Management LLC 1,494,386 $14,960,000 0.0% +16.8% 2.699%
2021-08-17 Caas Capital Management LP 62,496 $630,000 0.0% 0 0.113%
2021-08-16 Dragoneer Investment Group LLC 4,000,000 $40,040,000 0.5% 0 7.223%
2021-08-16 Royal Bank of Canada 156,113 $1,560,000 0.0% -10.6% 0.282%
2021-08-16 Morgan Stanley 95,046 $950,000 0.0% -65.7% 0.172%
2021-08-16 Goldman Sachs Group Inc. 1,259,348 $12,610,000 0.0% +10.2% 2.274%
2021-08-16 Wolfswood Holdings LLC 35,000 $350,000 0.9% 0 0.063%
2021-08-13 EJF Capital LLC 30,000 $300,000 0.0% 0 0.054%
2021-08-13 Alpine Global Management LLC 15,068 $150,000 0.0% 0 0.027%
2021-08-13 Glazer Capital LLC 78,785 $790,000 0.0% 0 0.142%
2021-08-13 Spring Creek Capital LLC 734,560 $7,350,000 0.4% -4.7% 1.327%
2021-08-13 Lincoln National Corp 25,535 $260,000 0.0% +21.1% 0.046%
2021-08-13 Geode Capital Management LLC 57,066 $570,000 0.0% 0 0.103%
2021-08-13 Finepoint Capital LP 1,838,417 $18,400,000 3.5% 0 3.320%
2021-08-12 Penserra Capital Management LLC 16,913 $170,000 0.0% 0 0.031%
2021-08-11 Element Capital Management LLC 1,495,000 $14,970,000 2.4% -8.3% 2.700%
2021-08-11 BlackRock Inc. 4,932,330 $49,370,000 0.0% -0.4% 8.907%
2021-08-11 Levin Capital Strategies L.P. 10,000 $100,000 0.0% 0 0.018%
2021-08-11 Picton Mahoney Asset Management 150,000 $1,500,000 0.0% 0 0.271%
2021-08-06 Magnetar Financial LLC 62,004 $620,000 0.0% 0 0.112%
2021-07-31 IFP Advisors Inc 18,026 $180,000 0.0% -28.5% 0.033%
2021-07-28 OTA Financial Group L.P. 21,000 $210,000 0.2% 0 0.038%
2021-05-19 Virtu Financial LLC 12,818 $130,000 0.0% 0 0.023%
2021-05-18 Millennium Management LLC 1,278,956 $13,070,000 0.0% 0 2.310%
2021-05-18 Castle Creek Arbitrage LLC 261,200 $2,660,000 0.2% 0 0.472%
2021-05-18 Berkley W R Corp 13,581 $140,000 0.0% 0 0.025%
2021-05-18 Morgan Stanley 277,296 $2,830,000 0.0% 0 0.501%
2021-05-18 Blackstone Group Inc. 2,495,000 $25,500,000 0.1% 0 4.506%
2021-05-18 Alyeska Investment Group L.P. 410,984 $4,200,000 0.1% 0 0.742%
2021-05-18 Radcliffe Capital Management L.P. 176,818 $1,810,000 0.1% 0 0.319%
2021-05-17 CNH Partners LLC 30,000 $310,000 0.0% 0 0.054%
2021-05-17 Royal Bank of Canada 174,631 $1,790,000 0.0% 0 0.315%
2021-05-17 CSS LLC IL 26,045 $270,000 0.0% 0 0.047%
2021-05-17 HBK Investments L P 550,000 $5,620,000 0.0% 0 0.993%
2021-05-17 Brookfield Asset Management Inc. 161,145 $1,650,000 0.0% 0 0.291%
2021-05-17 Goldman Sachs Group Inc. 1,142,602 $11,680,000 0.0% 0 2.063%
2021-05-14 Sculptor Capital LP 200,000 $2,040,000 0.0% 0 0.361%
2021-05-14 Spring Creek Capital LLC 770,500 $7,880,000 0.3% 0 1.391%
2021-05-14 Weiss Asset Management LP 1,346,497 $13,760,000 0.4% 0 2.432%
2021-05-14 TD Asset Management Inc. 334,600 $3,420,000 0.0% 0 0.604%
2021-05-14 Harspring Capital Management LLC 75,000 $770,000 0.1% 0 0.135%
2021-05-12 MYDA Advisors LLC 24,000 $250,000 0.1% 0 0.043%
2021-05-12 UBS Group AG 6,897 $70,000 0.0% 0 0.012%
2021-05-11 Boussard & Gavaudan Investment Management LLP 200,000 $2,029,999 0.2% 0 0.361%
2021-05-11 Element Capital Management LLC 1,630,000 $16,660,000 3.8% 0 2.944%
2021-05-10 Lincoln National Corp 21,090 $220,000 0.0% 0 0.038%
2021-05-07 BlackRock Inc. 4,950,000 $50,590,000 0.0% 0 8.939%
2021-05-07 Sowell Financial Services LLC 38,017 $380,000 0.0% 0 0.069%
2021-05-07 The PNC Financial Services Group Inc. 3,500 $36,000 0.0% 0 0.006%
2021-05-03 The Manufacturers Life Insurance Company 1,196,407 $12,230,000 0.0% 0 2.161%
2021-04-30 IFP Advisors Inc 25,219 $260,000 0.0% 0 0.046%
2021-04-29 Dupont Capital Management Corp 99,996 $1,020,000 0.0% 0 0.181%

SEC Filings

Form Type Form Description Filing Date Document Link
10-Q 10-Q 2021-11-12
8-K FORM 8-K 2021-11-02
8-K FORM 8-K 2021-08-20
10-Q FORM 10-Q 2021-08-11
10-Q FORM 10-Q 2021-06-15
8-K FORM 8-K 2021-06-04
10-K/A FORM 10-K/A 2021-05-26
8-K FORM 8-K 2021-05-20
NT 10-Q NT 10-Q 2021-05-12
10-K FORM 10-K 2021-03-04
SC 13G SC 13G 2021-02-16
SC 13G SCHEDULE 13G 2021-02-11
SC 13G 2021-02-08
SC 13G/A 2021-01-21
8-K FORM 8-K 2020-12-30
10-Q FORM 10-Q 2020-12-11
8-K/A FORM 8-K/A 2020-11-23
8-K FORM 8-K 2020-11-23
SC 13G 2020-11-20
8-K FORM 8-K 2020-11-17
424B4 424B4 2020-11-16
EFFECT 2020-11-12
3 3 2020-11-12
3 3 2020-11-12
3 3 2020-11-12
3 3 2020-11-12
3 3 2020-11-12
3 3 2020-11-12
3 3 2020-11-12
3 3 2020-11-12
3 3 2020-11-12
CERT 2020-11-12
8-A12B 8-A12B 2020-11-12
CORRESP 2020-11-12
S-1/A S-1/A 2020-11-12
CORRESP 2020-11-10
CORRESP 2020-11-10
UPLOAD 2020-11-10
CORRESP 2020-11-09
S-1/A S-1/A 2020-11-09
S-1/A S-1/A 2020-11-06
UPLOAD 2020-11-04
CORRESP 2020-10-26
S-1 S-1 2020-10-26
UPLOAD 2020-10-22
DRS 2020-09-28